HRs and corresponding 95% CIs for mortality after bone metastasis, comparing patients with bone metastasis only and patients with additional synchronous metastases
| Primary cancer | N (%) | Median survival time (days) | HR (95% CI) | Adjusted* HR (95% CI) | |
| Colon cancer | Bone metastasis only | 452 (91) | 105 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 47 (9) | 95 | 1.38 (1.02 to 1.87) | 1.48 (1.09 to 2.03) | |
| Rectum cancer | Bone metastasis only | 361 (90) | 114 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 39 (10) | 79 | 1.47 (1.06 to 2.05) | 1.44 (1.03 to 2.03) | |
| Lung cancer | Bone metastasis only | 2871 (84) | 74 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 532 (16) | 61 | 1.20 (1.10 to 1.32) | 1.27 (1.16 to 1.40) | |
| Malignant melanoma | Bone metastasis only | 172 (64) | 95 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 97 (36) | 75 | 1.26 (0.97 to 1.63) | 1.29 (0.99 to 1.69) | |
| Breast cancer | Bone metastasis only | 3268 (86) | 377 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 521 (14) | 170 | 1.42 (1.28 to 1.57) | 1.47 (1.33 to 1.63) | |
| Cervix cancer | Bone metastasis only | 67 (91) | 98 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 7 (9) | 46 | 1.06 (0.48 to 2.33) | 1.00 (0.42 to 2.38) | |
| Ovarian cancer | Bone metastasis only | 54 (83) | 170 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 11 (17) | 129 | 1.12 (0.56 to 2.23) | 1.08 (0.51 to 2.29) | |
| Prostate cancer | Bone metastasis only | 5726 (96) | 210 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 215 (4) | 109 | 1.55 (1.35 to 1.78) | 1.57 (1.36 to 1.80) | |
| Kidney cancer | Bone metastasis only | 609 (77) | 182 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 186 (23) | 105 | 1.33 (1.12 to 1.58) | 1.41 (1.18 to 1.69) | |
| Urinary bladder cancer | Bone metastasis only | 513 (94) | 68 | 1.0 | 1.0 |
| Bone+other synchronous metastases | 33 (6) | 56 | 1.14 (0.79 to 1.65) | 1.22 (0.84 to 1.77) |
↵*Adjusted by gender, age, Charlson Comorbidity Index Score and period of diagnosis.